- Open Access
Erratum: Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options
© Moreno et al. 2015
- Received: 23 March 2015
- Accepted: 23 March 2015
- Published: 28 July 2015
The original article was published in Radiation Oncology 2014 9:258
Current Ongoing trials for Prostate Cancer Oligometastases in 2014 (www.clinicaltrials.gov)
Radiotherapy for Oligometastatic Prostate Cancer
Efficacy and safety in patients with prymary active or not
2: CR and HN
Improvement in median progression-free survival in patients with metastatic prostate cancer over historic control rates in hormone receptive and castration resistant subgroups.
Improvement in overall survival of patients with metastatic prostate cancer.
University of Florida
Treatment failure rates in patients treated with stereotactic radiation for metastatic prostate cancer. after type of secondary outcome.
Quality of life in patients treated with stereotactic radiation for metastatic prostate cancer.
Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer
To determine the recommended SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting.
I. To estimate rates of > = grade 3 (CTCAE 4.0) adverse events other than a dose-limiting toxicity which is possibly, probably, or definitely related to treatment and which occurs within 6 months from the start of SBRT to multiple metastases.
NRG Oncology Foundation, Inc.
II. To estimate the rates of long-term adverse events occurring up to 2 years from the end of SBRT.
Collaborator: NCI RTOG
III. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical structure definition, treatment planning, image guidance and delivery.
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
Defer the start of ADT
2: A. Active surveillance
Androgen deprivation therapy free survival.
Quality of life
University Hospital, Ghent
B. Surgical or radiotherapy treatment of metastases
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer
Safety and Efficacy Study
Local and symptomatic control of oligometastases treated by SBRT
Biochemical progression rates
Chemotherapy-free survival and overall survival.
Analyze toxicities and quality of life of patients before and after treatment
Consorcio Hospitalario Provincial de Castellón
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.